Content

1. Rupee is more than a measure of price. It’s also a barometer of credibility
2. Global health governance must depend less on FDA

Rupee is more than a measure of price. It’s also a barometer of credibility

Why in News?

• Recent macroeconomic trends (2025–26) show persistent BoP pressures, weak FPI inflows, and rupee volatility, raising concerns over currency stability and macroeconomic credibility.

Issue in Brief

• The Indian Rupee (INR) is not merely an exchange rate variable but a macroeconomic credibility indicator, reflecting investor confidence, capital flows, and external sector stability.
• Sustained depreciation risks triggering inflation, capital flight, and balance sheet stress, undermining long-term economic growth prospects.

Relevance

• GS Paper III: Economy (External Sector, Exchange Rate, Inflation), Banking & Monetary Policy
• GS Paper II: Governance (RBI policy credibility, macroeconomic stability)

Practice Question

• “The exchange rate of a currency reflects not just economic fundamentals but also macroeconomic credibility. Analyse the factors influencing rupee stability and the policy challenges associated with it.” (250 words)

Static Background and Basics

• Exchange rate is the price of one currency in terms of another, determined by demand-supply dynamics in forex markets under managed float regime in India.
• RBI follows a managed floating exchange rate system, intervening to curb excessive volatility without targeting a fixed level.
• India’s forex reserves stood around $640+ billion (2024–25), providing buffer against external shocks.
• Current Account Deficit (CAD) becomes critical as India imports ~85% of crude oil, making rupee sensitive to global commodity prices.

Core Economic Theories 

Dornbusch Overshooting Model

• Due to sticky goods prices and flexible financial markets, exchange rates adjust sharply in the short run, often overshooting equilibrium levels before stabilising.
• Explains why currencies fall faster and deeper than macroeconomic fundamentals justify, especially during crises.

Mundell-Fleming Model (Impossible Trinity)

• A country cannot simultaneously maintain:
  • Fixed exchange rate
  • Free capital mobility
  • Independent monetary policy
• India manages trade-offs by allowing partial flexibility in exchange rate with controlled interventions.

Dimensions

Economic Dimension

• Currency depreciation initially improves export competitiveness, but sustained decline leads to imported inflation, especially in oil-dependent economies like India.
• India’s CAD vulnerability persists, as high import dependence offsets export gains from weaker currency.
• Persistent depreciation increases external debt burden, especially for firms with foreign currency borrowings.

Financial and External Sector Dimension

• FPI flows volatile: Positive inflows recorded in only 1 out of last 5 years (till 2026), weakening capital account stability.
• Continued outflows create funding pressure on CAD, increasing dependence on reserves or external borrowing.
• Currency volatility reduces investor confidence, discouraging long-term capital inflows and increasing risk premium.

Inflation and Welfare Dimension

• Depreciation acts as an implicit tax on citizens, increasing cost of imported goods such as fuel, fertilisers, and electronics.
• Leads to cost-push inflation, eroding real incomes and disproportionately affecting poor households.
• Export gains are often neutralised by higher input costs, especially in import-dependent industries.

Governance and Policy Dimension

• RBI faces trade-offs:
  • Raising interest rates stabilises currency but slows growth
  • Allowing depreciation fuels inflation and instability
• Use of tools like sterilised interventions, swap windows, and reserve requirements reflects calibrated policy response.

Historical Lessons

Global Financial Crisis (2008–09)

• RBI reduced repo rate from 9% to 4.75%, injected ₹2.25 lakh crore liquidity, stabilising markets.
• Fiscal stimulus of ~3% of GDP boosted demand but raised fiscal deficit to 6.5% of GDP.

Taper Tantrum (2013)

• Rupee depreciated ~20%, triggered by US Fed policy signals.
• Policy response:
  • FCNR(B) deposit schemes
  • Oil swap windows
  • Gold import duty hike (6% → 10%)
• CAD reduced from 4.8% to 1.3% of GDP, restoring macro stability.

Global and Structural Dimension

• Emerging markets like Turkey, Brazil faced severe inflation due to currency depreciation, highlighting limits of export-led devaluation strategies.
• Persistent depreciation reflects structural weaknesses: low export diversification, energy dependence, and weak manufacturing base.

Geopolitical and Trade Dimension

• External pressures such as tariffs, Section 301 investigations, geopolitical tensions, and AI-driven trade disruptions influence currency volatility.
• Global monetary tightening cycles amplify capital outflows from emerging markets like India.

Challenges and Risks

• Persistent BoP deficit and weak capital inflows create sustained downward pressure on rupee stability.
• Over-reliance on monetary tools risks policy ineffectiveness during supply-side shocks like oil price spikes.
• High import dependence in energy and electronics limits benefits of depreciation-led export competitiveness.
• Currency volatility increases corporate balance sheet risks, especially for firms with unhedged foreign liabilities.
• Rising reputation risk may deter both new and existing investors, affecting long-term capital formation.

Way Forward

• Strengthen external sector resilience by diversifying exports and reducing dependence on imported inputs, especially in energy and electronics sectors.
• Enhance energy security through renewable expansion and strategic reserves to reduce oil import vulnerability.
• Improve investment climate via policy stability, ease of doing business, and regulatory predictability to attract sustained FDI inflows.
• Use coordinated monetary-fiscal strategy, avoiding excessive reliance on interest rate adjustments during supply shocks.
• Expand inclusion of petroleum products and electricity under GST to improve fiscal efficiency and reduce cascading costs.
• Maintain adequate forex reserves buffer and deploy calibrated interventions to prevent disorderly currency movements.

Prelims Pointers

• India follows managed floating exchange rate system
• CAD + capital flows = Balance of Payments (BoP)
• Dornbusch Model → explains exchange rate overshooting
• Mundell-Fleming → Impossible Trinity concept
• FCNR(B) deposits used during 2013 crisis stabilisation

Global health governance must depend less on FDA

Why in News?

• Recent 2025–2026 developments within the US FDA, including leadership turnover, regulatory shifts, and policy changes in AI and biologics, have raised concerns over global regulatory stability.

Issue in Brief

• The US Food and Drug Administration (FDA) acts as a global benchmark regulator, influencing drug approvals, clinical trials, and regulatory standards across multiple countries.
• Current institutional instability within FDA risks delays, uncertainty, and cascading disruptions in global drug approval ecosystems.

Relevance

• GS Paper II: International Relations, Global Health Governance, Institutions
• GS Paper III: Science & Technology (Pharma, Biotech regulation)

Practice Question

• “Excessive reliance on a single national regulator like the US FDA creates systemic risks in global health governance. Critically examine and suggest alternatives.” (250 words)

Static Background and Basics

• The U.S. Food and Drug Administration was established in 1906 (Pure Food and Drugs Act) and operates under the US Department of Health and Human Services.
• It regulates drugs, vaccines, biologics, medical devices, diagnostics, and food safety, covering products worth ~20% of US consumer spending.
• Other key global regulators include:
  • European Medicines Agency (EU)
  • Central Drugs Standard Control Organisation (India)
• Global regulatory cooperation guided by International Council for Harmonisation (ICH) ensures standardisation of safety, quality, and efficacy norms.

Conceptual Foundation: Regulatory Reliance Model

• Many low- and middle-income countries adopt “regulatory reliance pathways”, using approvals from FDA/EMA to fast-track domestic approvals without duplicating full review processes.
• This reduces:
  • Approval timelines
  • Regulatory burden
• Ensures minimum global safety standards despite limited domestic capacity.

Dimension

Governance and Institutional Dimension

• FDA serves as a de facto global standard-setter, influencing regulatory frameworks, clinical trial norms, and approval pathways across developing and developed economies.
• Leadership instability in critical divisions (e.g., biologics) creates policy uncertainty in high-risk areas like vaccines and gene therapy regulation.
• Budget constraints and structural reforms within FDA may reduce institutional predictability and regulatory consistency globally.

Global Health Governance Dimension

• Over-reliance on FDA creates systemic vulnerability, where regulatory disruptions in one country affect multiple national health systems.
• Highlights need for multipolar regulatory architecture, reducing concentration of authority in a single institution.
• Strengthening regional regulators improves resilience and decentralisation in global health governance systems.

Economic and Pharmaceutical Industry Dimension

• FDA approval is considered gold standard for global market access, influencing investment decisions and pharmaceutical R&D strategies.
• Pharmaceutical companies design clinical trials aligned with FDA standards, affecting global research protocols and innovation pipelines.
• Regulatory uncertainty increases cost of compliance and delays product commercialisation, affecting global supply chains.

Science and Technology Dimension

• FDA plays a critical role in regulating emerging technologies such as AI in healthcare, digital health tools, and clinical decision support systems.
• Changes in FDA guidelines influence global standards for AI validation, safety protocols, and ethical use in medicine.
• Instability may slow adoption of cutting-edge innovations like gene therapy and personalised medicine.

Social and Ethical Dimension

• Delays in approvals due to regulatory uncertainty affect timely access to life-saving medicines and vaccines, especially in developing countries.
• Raises concerns of equity in global health, as countries dependent on FDA may face delays in access to critical healthcare technologies.
• Over-centralisation of regulatory authority raises ethical issues of global dependence on a single national institution.

India-Specific Dimension

• India’s Central Drugs Standard Control Organisation increasingly aligns with global standards but still relies partly on FDA approvals for accelerated pathways and benchmarking.
• India is expanding regulatory capacity through:
  • Strengthening CDSCO
  • Enhancing clinical trial ecosystem
• Presents opportunity to emerge as a regional regulatory hub for Global South countries.

Challenges and Risks

• Excessive reliance on FDA creates systemic regulatory dependency, limiting autonomy of national regulators in decision-making.
• Leadership turnover within FDA introduces uncertainty in approval timelines, especially in biologics and advanced therapies.
• Divergence in regulatory standards may increase compliance burden for global pharmaceutical firms.
• Limited capacity in developing countries constrains their ability to independently evaluate complex drugs and technologies.
• Fragmentation of regulatory standards could lead to inconsistent safety and efficacy benchmarks globally.

Way Forward

• Strengthen national regulatory institutions like CDSCO, enhancing technical capacity, staffing, and infrastructure for independent drug evaluation.
• Promote regional regulatory cooperation frameworks (e.g., Asia-Africa collaboration) to reduce dependence on Western regulators.
• Enhance participation in ICH and WHO regulatory harmonisation initiatives to align global standards while maintaining autonomy.
• Develop robust domestic clinical trial ecosystems, reducing reliance on foreign regulatory benchmarks.
• Encourage multi-regulator validation models, where approvals consider inputs from multiple global agencies rather than a single authority.
• Invest in AI-driven regulatory tools to improve efficiency, transparency, and speed of drug approval processes.

Prelims Pointers

• FDA established: 1906 (Pure Food and Drugs Act)
• FDA regulates:
  • Drugs, biologics, devices, food
• EMA:
  • European Union drug regulator
• CDSCO:
  • India’s national drug regulatory authority
• ICH:
  • Harmonises global drug regulatory standards